Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Inverness unveils new Clearview TB ELISA rapid diagnostic kit for HIV patients

Inverness Medical Innovations : 04 August, 2008  (New Product)
Inverness Medical has launched the company’s new Clearview TB ELISA at the International AIDS Conference (AIDS 2008) in Mexico City.
Tuberculosis (TB) is a leading cause of death in HIV infected patients, and the urine based Clearview TB ELISA LAM antigen test can provide a much needed aid in the diagnosis of TB in TB/HIV co-infected patients.

HIV is driving the TB epidemic in many countries such as sub-Saharan Africa, Asia and South America where HIV infection amongst the population is high. Inverness Medical is now able to offer a rapid diagnostic kit using ELISA (Enzyme Linked Immunosorbent Assay) technology capable of aiding the diagnosis of TB in these vulnerable patients where previously existing tests have failed.

Traditional sputum smear tests for TB incur limitations when used as a primary diagnostic test in co-infected HIV-TB patients, with a sensitivity falling to as low as 20 percent in patients who are also HIV infected (Ref 1). Clearview TB ELISA uses antibodies specific to the antigen lipoarabinomannan (LAM) which forms part of the TB cell wall.

The elevated levels of the LAM antigen within the urine of TB/HIV co-infected patients provide a specific diagnostic target. When targeting this specific antigen, clinical data shows that in TB-HIV co-infected patients detection rates increase to 80.3 percent (Ref 2). The use of urine also offers the clinician the advantage of a sample material which is safer and far less invasive than conventional sputum sample collection.

The new, user-friendly, Clearview test screens for the LAM antigen in urine samples in less than three hours, faster than bacterial cultures that can take up to six weeks to develop (Ref 1). By using the LAM ELISA technology, Inverness Medical is leading the way in reducing the prevalence of this preventable and curable disease in areas with a large HIV population through effective early diagnosis.

Inverness Medical will be exhibiting the Clearview TB ELISA kit on stand 211 at AIDS 2008 from 3 to 8 August 2008.

Ref 1 - World Health Organization (2006) Diagnostics for Tuberculosis: global demand and market potential.

Ref 2 - Boehme C et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis.Trans R Soc Trop Med Hyg. 99 (12):893-900, 2005.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo